EUVIMEDEUVIMED entdecken
Übersichtsarbeit

A comprehensive review of sex differences in the clinical outcomes to immunotherapy on solid tumors

Juan Carlos Redondo-González, Luis Posado-Domínguez, Laura Corvo-Félix, Lorena Bellido Hernández, Iñigo San Miguel-Arregui, Emilio Fonseca-Sánchez, Alejandro Olivares-Hernández, Edel Del Barco-Morillo

Clinical and Translational Oncology · 2025

DOI: 10.1007/s12094-025-04142-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Oncology, 2025. Verfasst von Juan Carlos Redondo-González und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, University Hospital of Salamanca, Paseo de San Vicente, 182, 37007, Salamanca, Spain. Hauptthemen laut MEDLINE: Immunotherapy, Neoplasms, Sex Characteristics. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy has led to a paradigm shift in the treatment of various tumors. However, the results obtained sometimes show heterogeneous and inconsistent responses despite the presence of biomarkers such as PD-L1. Recent studies suggest that the efficacy of immunotherapy may vary based on sex, although the findings remain controversial. The aim of this comprehensive review is to evaluate the available evidence and the biological mechanisms that could explain these differences. Some recent meta-analyses have suggested a greater overall survival benefit for males. Theoretical models, supported by in vivo studies in different animal species, are currently focused on the implications of the tumor microenvironment, hormonal factors in the antitumor activity of the immune system and their correlation with the patient's sex. Other chromosomal sex-specific alterations could be influenced by epigenetic changes affecting genetic material. Prospective studies are needed to further investigate the uncertain relationship between sex and immunotherapy in humans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyNeoplasmsSex CharacteristicsHumansMaleFemaleTumor MicroenvironmentAnimalsSex FactorsTreatment Outcome

Stichwörter der Autor:innen

ImmunotherapyOutcomesSexSolid tumors

Autor:innen und Institutionen

  • Medical Oncology Department, University Hospital of Salamanca, Paseo de San Vicente, 182, 37007, Salamanca, Spain.
  • Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain.
  • Faculty of Medicine, University of Salamanca, Salamanca, Spain.
  • Radiation Oncology Department, University Hospital of Salamanca, Salamanca, Spain.
  • Medical Oncology Department, University Hospital of Salamanca, Paseo de San Vicente, 182, 37007, Salamanca, Spain. aolivares@saludcastillayleon.es.
  • Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain. aolivares@saludcastillayleon.es.

Zitieren

APA

Redondo-González, J. C., Posado-Domínguez, L., Corvo-Félix, L., Bellido Hernández, L., Miguel-Arregui, I. S., Fonseca-Sánchez, E., Olivares-Hernández, A., & Del Barco-Morillo, E. (2025). A comprehensive review of sex differences in the clinical outcomes to immunotherapy on solid tumors. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-025-04142-2

Vancouver

Redondo-González JC, Posado-Domínguez L, Corvo-Félix L, Bellido Hernández L, Miguel-Arregui IS, Fonseca-Sánchez E, et al. A comprehensive review of sex differences in the clinical outcomes to immunotherapy on solid tumors. Clinical and Translational Oncology. 2025. doi:10.1007/s12094-025-04142-2

BibTeX
@article{RedondoGonzlez2025,
  author = {Redondo-González, Juan Carlos and Posado-Domínguez, Luis and Corvo-Félix, Laura and Bellido Hernández, Lorena and Miguel-Arregui, Iñigo San and Fonseca-Sánchez, Emilio and Olivares-Hernández, Alejandro and Del Barco-Morillo, Edel},
  title = {A comprehensive review of sex differences in the clinical outcomes to immunotherapy on solid tumors},
  journal = {Clinical and Translational Oncology},
  year = {2025},
  doi = {10.1007/s12094-025-04142-2}
}
Kostenlos starten →